Back to top
more

Cerner Corporation (CERN)

(Delayed Data from NSDQ)

$68.47 USD

68.47
2,167,881

+0.46 (0.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $68.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cerner (CERN) Set to Improve Patient Experience With New Deal

by Zacks Equity Research

The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.

Here's Why You Should Hold Onto Cerner (CERN) Stock for Now

by Zacks Equity Research

Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.

NextGen's (NXGN) Population Health Picked by Ohio-Based UH

by Zacks Equity Research

NextGen's (NXGN) EHR services are expected to enhance patient outcomes at UH.

Varian's AI-Driven Ethos Solution to Boost Global Cancer Care

by Zacks Equity Research

Varian (VAR) expects the Ethos launch to boost its Oncology Systems segment.

Sreyoshi Mukherjee headshot

Cybersecurity a Top Priority for Healthcare: 3 Stocks to Watch

by Sreyoshi Mukherjee

As cybersecurity is the need of the hour for U.S. healthcare companies, let's keep an eye on three stocks.

SYNH or CERN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SYNH vs. CERN: Which Stock Is the Better Value Option?

Sreyoshi Mukherjee headshot

Bright Near-Term Outlook for Medical Info Systems Industry

by Sreyoshi Mukherjee

Growth prospects look bright for the Zacks Medical Info Systems industry, thanks to rising need for curtailing medical expenses and AI.

Cerner (CERN) Down 1.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OptimizeRx (OPRX) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

OptimizeRx's (OPRX) second-quarter 2019 results are likely to benefit from increased sales of core financial and brand messaging products.

MDRX or CERN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MDRX vs. CERN: Which Stock Is the Better Value Option?

Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.

Cerner (CERN) Q2 Earnings Top Estimates

by Zacks Equity Research

Cerner (CERN) delivered earnings and revenue surprises of 3.13% and -0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Offing for Cerner's (CERN) Earnings in Q2?

by Zacks Equity Research

Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.

Here's Why Investors Should Consider Cerner (CERN) Stock

by Zacks Equity Research

For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.

Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NextGen Inks Deal With Appriss Health, Boosts EHR System

by Zacks Equity Research

NextGen (NXGN) integrates Appriss Health prescription monitoring and tracking analytics into NextGen Office that is likely to enhance the former's EHR system.

Omnicell (OMCL) Catches Eye: Stock Jumps 8.2%

by Zacks Equity Research

Omnicell (OMCL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Urmimala Biswas headshot

Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD

by Urmimala Biswas

The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.

MDRX vs. CERN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MDRX vs. CERN: Which Stock Is the Better Value Option?

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.

Boston Scientific Strong on Growth Goals and Future Launches

by Zacks Equity Research

This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.

Teleflex (TFX) Shares Down on Respiratory Care Product Recall

by Zacks Equity Research

Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.

Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Bruker (BRKR) gains from several crucial product launches and acquisitions.

Hill-Rom (HRC) Gains on Product Launch, Prudent Buyouts

by Zacks Equity Research

The contribution from new products is substantial to bolster top-line growth during the first half of fiscal 2019 at Hill-Rom (HRC).

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

GNC Holdings (GNC) continues to witness investors' confidence, courtesy of a few positive factors like strategic new partnerships.